---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025177"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:28:23.112761+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Nasdaq notified Akari on Nov 24, 2025 that ADS closing bid price below $1.00 for 30 consecutive business days.
- Company has 180 calendar days (until May 25, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not cured by May 25, 2026, Akari may be eligible for an additional 180-day period if other listing standards are met.
- Failure to regain compliance could result in delisting of ADSs from Nasdaq Capital Market.
- Akari may consider an ADS ratio change to address the bid price deficiency.

## SEC filing metadata
- accession: 0001493152-25-025177
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315225025177/0001493152-25-025177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315225025177/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025177
- JSON: https://secwatch.observer/filing/0001493152-25-025177.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025177.txt

## Source-grounded claims
- claim_id: e39eb564ac91be664b3be454336db232342673d5
  claim: Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  evidence_excerpt: November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busines
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000149315225025177/0001493152-25-025177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.